Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Vivesto AB ( (SE:VIVE) ) just unveiled an announcement.
Vivesto AB held its Annual General Meeting on May 8, 2025, where several key resolutions were passed. These included the adoption of the 2024 financial statements, re-election of board members and auditors, and approval of remuneration reports. Notably, the board was authorized to issue shares and financial instruments to enhance financial flexibility and support strategic acquisitions, indicating a focus on expanding the company’s capital base and shareholder diversity.
More about Vivesto AB
Vivesto AB is a Swedish development company focused on providing new treatment options for hard-to-treat cancers with significant medical needs and market potential. Its project portfolio includes Cantrixil, developed for blood cancer, and Paccal Vet, a veterinary oncology program undergoing clinical trials for dogs with splenic hemangiosarcoma.
Average Trading Volume: 541,215
Current Market Cap: SEK124M
For a thorough assessment of VIVE stock, go to TipRanks’ Stock Analysis page.